Therefore, this study aimed to appraise the diagnostic value of intraprostatic PSMA uptake in risk classification of exclusively untreated, newly diagnosed PCa patients receiving 18F-DCFPyL PET/CT that were confirmed by the later MRI/transrectal ultrasound (TRUS)-fusion biopsy or the specimens after prostatectomy. The gene discussed is FOLH1; the disease is posterior cortical atrophy.